Prognostic factors and optimal timing for initiating adjuvant chemotherapy in stage IIIC gastric cancer

Table 2 Univariate and multivariate analyses of clinicopathologic factors for disease-free survival of patients with stage IIIC gastric cancer

Variable	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Gender	1.170 (0.594-2.305)	0.649	-	-
Age (years)	4.776 (2.253-10.126)	< 0.001	5.151 (2.200-12.060)	< 0.001
Tumor location	0.815 (0.581-1.142)	0.234	-	-
BMI	0.841 (0.489-1.448)	0.532	-	-
Atrophic gastritis	0.985 (0.514-1.888)	0.965	-	-
CEA (μg/L)	2.833 (1.486-5.401)	0.002	2.997 (1.404-6.400)	0.005
CA19-9 (kU/L)	1.682 (0.875-3.232)	0.119	-	-
PLR	0.954 (0.502-1.812)	0.886	-	-
NLR	1.726 (0.909-3.278)	0.095	-	-
pT stage	1.119 (0.564-2.221)	0.748	-	-
Ki-67	0.993 (0.485 2.031)	0.984	-	-
HER-2	0.043 (0.001-7.247)	0.230	-	-
EBER	1.494 (0.530-4.213)	0.448	-	-
P53	0.825 (0.440-1.545)	0.548	-	-
pMMR	0.380 (0.091-1.583)	0.184	-	-
Vascular invasion	0.980 (0.383-2.507)	0.966	-	-
Nerve invasion	0.798 (0.284-2.247)	0.670	-	-
Tumor size (cm)	0.718 (0.380-1.353)	0.305	-	-
Histological differentiation	0.283 (0.037-2.144)	0.222	-	-
Borrmann classification	1.185 (0.855-1.642)	0.309	-	-
MLR	2.481 (1.094-5.624)	0.030	2.404 (1.048-5.519)	0.039
TI	1.014 (1.006-1.021)	< 0.001	1.002 (1.000-1.005)	0.046
Cycle	0.355 (0.211-0.597)	< 0.001	0.667 (0.372-1.195)	0.174

HR: Hazard ratio; CI: Confidence interval; BMI: Body mass index; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; PLR: Platelet-to-lymphocyte ratio; NLR: Neutrophil-to-lymphocyte ratio; pT: Pathological T; EBER: Epstein-Barr virus-encoded small RNA status; HER-2: Human epidermal growth factor receptor-2; pMMR: Proficient mismatch repair or deficient mismatch repair; MLR: Metastatic lymph node ratio; TI: Time interval.